April 05, 2021
A phase II trial of a novel, lesion-directed antithrombotic agent shows no effect on preventing myocardial injury in low-risk patients undergoing PCI, but the safety profile was good with few bleeding events. Trialists believe the disappointing results don’t rule out a role for the agent in higher-risk settings.
Revacept (advanceCOR), an intravenous, competitive antagonist to platelet glycoprotein VI (GPVI), efficiently binds to collagen and effectively mimics the GPVI pathway, blocking platelet aggregation. The appeal of the agent stems from prior studies suggesting that it would permit
fast and powerful platelet inhibition at the site of the atherosclerotic plaque injury, without increasing the risk of bleeding more systemically. Past research has shown limited success with a similar agent derived from snake venom.